Mid Cap Biotechnology
Stocks Ranked by
Market Capitalization
No stocks matched the selected filter criteria.
Mid Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 74 mid cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $2B and $10B — worth a combined $351B.
The largest by market cap are Madrigal Pharmaceuticals (MDGL) at $10B, Vaxcyte (PCVX) at $9.5B and Twist Bioscience (TWST) at $9.3B.
Among institutional investors, Definium Therapeutics (DFTX) drew the most net new fund positions in Q2 2026: 149 funds opened new positions, taking total fund holders up 114 (46%) quarter-over-quarter.
- Combined market cap: $351B across 74 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Madrigal Pharmaceuticals (MDGL), $10B market cap.
- Most net new fund positions in Q2 2026: Definium Therapeutics (DFTX), +114 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.